Last update 20 Mar 2025

CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)

Overview

Basic Info

Drug Type
CAR-T
Synonyms-
Target
CD38 x CLL-1
Action
modulators
Mechanism
CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), CLL-1 modulators(C-Type lectin domain family 12 member A modulators), Immunologic cytotoxicity
+ [1]
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesOther Diseases
Active Indication
Acute Promyelocytic LeukemiaRefractory acute myeloid leukemia
Inactive Indication
Relapsing acute myeloid leukemia
Originator Organization
Gracell Biotechnologies (Shanghai) Co., Ltd.Gracell Biotechnologies (Shanghai) Co., Ltd.
Active Organization
Gracell Biotechnologies (Shanghai) Co., Ltd.Gracell Biotechnologies (Shanghai) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
NCT06880354
/ Not yet recruitingPhase 1IIT
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
100 Clinical Results associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
Login to view more data
100 Translational Medicine associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
Login to view more data
100 Patents (Medical) associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
Login to view more data
100 Deals associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapsing acute myeloid leukemiaPhase 3
China
Gracell Biotechnologies (Shanghai) Co., Ltd.Gracell Biotechnologies (Shanghai) Co., Ltd.
10 Oct 2023
Acute Promyelocytic LeukemiaPhase 1
China
Gracell Biotechnologies (Shanghai) Co., Ltd.Gracell Biotechnologies (Shanghai) Co., Ltd.
31 Mar 2025
Refractory acute myeloid leukemiaPhase 1
China
Gracell Biotechnologies (Shanghai) Co., Ltd.Gracell Biotechnologies (Shanghai) Co., Ltd.
31 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free